ThromboGenics and BioInvent will split the proceeds 60/40.



ThromboGenics and BioInvent inked a deal with Roche covering development and commercialization of TB-403, their jointly developed Phase I anticancer agent. In exchange for a worldwide exclusive license to TB-403, Roche will make an upfront payment of $77.41M (EUR50 million).

In addition, ThromboGenics and BioInvent could potentially receive up to $696.89M (EUR450M) based on the successful completion of a series of development and commercial milestones for multiple indications, as well as double-digit royalties on potential product sales, including any backup antibodies based on inhibition of PlGF. TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology where the therapeutic potential of anti-PlGF agents to treat cancer was first developed.

ThromboGenics will receive 60% and BioInvent 40% of the revenue from the deal.


Related Links:


ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 


Flanders Striving to Attract Biotechnology








This site uses Akismet to reduce spam. Learn how your comment data is processed.